GlassScriptPhysician profile
Rahman Ryan Subrati
NPI 1932479094
$3,541.86
in general payments reported to CMS, 2019-2025
27 companies · $1,009 in 2025
The $1,009 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $460 · 2020: $176 · 2021: $101 · 2022: $370 · 2023: $494 · 2024: $931 · 2025: $1,009.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,426 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,425.57 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $688.95 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $623.79 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $480.88 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $420.29 | 2019-2025 | |
| Glaxosmithkline, LLC. | $250.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $209.09 | 2020-2025 | Ubrelvy, Vraylar |
| Astellas Pharma US INC | $188.48 | 2019-2025 | Veozah |
| Currax Pharmaceuticals LLC | $134.41 | 2020-2024 | Contrave |
| Exact Sciences Corporation | $89.85 | 2023-2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $72.34 | 2022 | |
| Amgen INC. | $71.27 | 2019-2020 | |
| Amarin Pharma, INC. | $42.81 | 2019-2022 | |
| Endo Pharmaceuticals INC. | $40.14 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.05 | 2023-2025 | Jardiance |
| Ars Pharmaceuticals Operations, INC. | $19.69 | 2025 | Neffy |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $19.63 | 2025 | Korlym |
| Kyowa Kirin, INC. | $18.51 | 2025 | |
| Abbott Laboratories | $16.42 | 2023 | Freestyle Libre 3 |
| Kaleo, INC. | $15.80 | 2023 | Auvi-Q |
| Genentech USA, INC. | $15.00 | 2019 | |
| Vbi Vaccine (Delaware) INC. | $13.99 | 2023 | Prehevbrio |
| Kowa Pharmaceuticals America, INC. | $13.70 | 2019 | |
| Althera Pharmaceuticals LLC | $13.11 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.66 | 2021 | |
| Horizon Therapeutics Plc | $12.50 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.06 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rahman Subrati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.